PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33599867-7	2021	CONCLUSION: High expression of immunohistochemically detected p53 was strongly and significantly associated with decreased OS and BCSS than low p53 expression, suggesting that p53 may be a powerful prognostic factor in HR-positive, HER2-negative breast cancer patients receiving NAC.	nac	279-282	tumor protein p53	Homo sapiens	62-65	
33325610-9	2021	Co-administration of the ROS inhibitor NAC largely abolished the up-regulated p53 protein level, and rescued the suppressed viability and colony formation ability in butein-exposed U-2 OS cells.	nac	39-42	tumor protein p53	Homo sapiens	78-81	
32218822-7	2020	In regard to TP53 mutation, the rate of TP53 mutation in the NAC-resistant cases was significantly higher compared with NAC-sensitive cases.	nac	61-64	tumor protein p53	Homo sapiens	13-17	
32218822-7	2020	In regard to TP53 mutation, the rate of TP53 mutation in the NAC-resistant cases was significantly higher compared with NAC-sensitive cases.	nac	61-64	tumor protein p53	Homo sapiens	40-44	
32218822-7	2020	In regard to TP53 mutation, the rate of TP53 mutation in the NAC-resistant cases was significantly higher compared with NAC-sensitive cases.	nac	120-123	tumor protein p53	Homo sapiens	13-17	
32218822-7	2020	In regard to TP53 mutation, the rate of TP53 mutation in the NAC-resistant cases was significantly higher compared with NAC-sensitive cases.	nac	120-123	tumor protein p53	Homo sapiens	40-44	
32218822-9	2020	These results indicated that gene mutation can be profiled and monitored using liquid biopsy-based CAPP-Seq in patients with advanced ovarian cancer with NAC treatment, and TP53 mutation in the ctDNA and bTMB may be novel biomarkers that can be used for patient monitoring during NAC treatment.	nac	280-283	tumor protein p53	Homo sapiens	173-177	
31464976-8	2020	Inhibition of ROS generation by NAC or p38 MAPK signaling by SB203580 attenuated the p53-mediated cell cycle arrest and apoptosis induced by LY.	nac	32-35	tumor protein p53	Homo sapiens	85-88	
31428569-10	2019	Apoptosis of A549 cells was decreased after transfected with p53 shRNA or treated with reactive oxygen species inhibitor NAC and p38MAPK inhibitor SB203580, suggesting that the p53/ROS/p38MAPK pathway appeared to mediate the LBP-induced apoptosis of A549 cells.	nac	121-124	tumor protein p53	Homo sapiens	61-64	
31428569-10	2019	Apoptosis of A549 cells was decreased after transfected with p53 shRNA or treated with reactive oxygen species inhibitor NAC and p38MAPK inhibitor SB203580, suggesting that the p53/ROS/p38MAPK pathway appeared to mediate the LBP-induced apoptosis of A549 cells.	nac	121-124	tumor protein p53	Homo sapiens	177-180	
24335178-2	2013	In this study, we sought to examine the hypothesis that neoadjuvant chemotherapy (NAC) is a better approach with improved prognosis and outcomes after laparoscopical radical hysterectomy (LRH) on patients with cervical cancer and to elucidate the potential roles of the p53:miR-34a:E2F1 and the p53:miR-605:Mdm2 signaling pathways in this therapy.	nac	82-85	tumor protein p53	Homo sapiens	270-273	
28910957-10	2017	Among them, the effect of NAC in patients with two or more genes copy number variations of c-Myc, CCND1, p53, p16 were poorer than that in patients with one or not gene copy number variations (P=0.000).	nac	26-29	tumor protein p53	Homo sapiens	105-108	
25834606-8	2015	Multivariate analysis showed that only p53 expression was independently associated with pCR to NAC (odds ratio, 3.961; p=0.003).	nac	95-98	tumor protein p53	Homo sapiens	39-42	
25834606-11	2015	CONCLUSION: Expression of p53 was significantly associated with pCR after NAC in patients with TNBC, suggesting that this biomarker might be particularly valuable in identifying TNBC patients prone to have residual disease after NAC.	nac	74-77	tumor protein p53	Homo sapiens	26-29	
25834606-11	2015	CONCLUSION: Expression of p53 was significantly associated with pCR after NAC in patients with TNBC, suggesting that this biomarker might be particularly valuable in identifying TNBC patients prone to have residual disease after NAC.	nac	229-232	tumor protein p53	Homo sapiens	26-29	
24662134-1	2014	BACKGROUND: The aim of this study was to evaluate association of expression of survivin and p53 with the effects of neoadjuvant chemotherapy (NAC) in patients with advanced ovarian cancer (AOC).	nac	142-145	tumor protein p53	Homo sapiens	92-95	
23804139-5	2013	In a comparison between the 9 (5%) sensitive patients and 30 (16%) insensitive patients, overexpression of p53 but not overexpression of either HER2 or EGFR was associated with a good response to NAC.	nac	196-199	tumor protein p53	Homo sapiens	107-110	
23804139-6	2013	p53 (p=0.045) and histological grade 3 (p=0.011) were important and significant predictors of the response to NAC.	nac	110-113	tumor protein p53	Homo sapiens	0-3	
23804139-10	2013	We conclude that the level of p53 expression in the CNB was an effective and reliable predictor of treatment response to NAC.	nac	121-124	tumor protein p53	Homo sapiens	30-33	
31372050-10	2019	Good response to NAC was associated with p53 expression.	nac	17-20	tumor protein p53	Homo sapiens	41-44	
28910957-12	2017	Conclusion: These results indicated that the copy number variations of c-Myc, CCND1, p53, and p16 in patients were significant correlation with poor effect of NAC.	nac	159-162	tumor protein p53	Homo sapiens	85-88	
27637603-10	2017	CONCLUSIONS: The presence of serum p53 antibody can be used as a novel, noninvasive predictor of the pathological tumor response to NAC with DCF in ESCC patients.	nac	132-135	tumor protein p53	Homo sapiens	35-38	
24335178-2	2013	In this study, we sought to examine the hypothesis that neoadjuvant chemotherapy (NAC) is a better approach with improved prognosis and outcomes after laparoscopical radical hysterectomy (LRH) on patients with cervical cancer and to elucidate the potential roles of the p53:miR-34a:E2F1 and the p53:miR-605:Mdm2 signaling pathways in this therapy.	nac	82-85	tumor protein p53	Homo sapiens	295-298	
24335178-10	2013	Furthermore, molecular biology analyses revealed that the protein and mRNA levels of p53 were both markedly increased in patients who received NAC than those who did not, and oppositely, the levels of E2F1 and Mdm2 were significantly lower in the NAC+LRH patients than in the LRH patients.	nac	143-146	tumor protein p53	Homo sapiens	85-88	
24335178-10	2013	Furthermore, molecular biology analyses revealed that the protein and mRNA levels of p53 were both markedly increased in patients who received NAC than those who did not, and oppositely, the levels of E2F1 and Mdm2 were significantly lower in the NAC+LRH patients than in the LRH patients.	nac	247-250	tumor protein p53	Homo sapiens	85-88	
24335178-14	2013	CONCLUSION: These findings not only indicate NAC as a rational approach for better treatment of cervical cancer with improved therapeutic outcomes, due partly to the ability of cisplatin to promote the p53:miR-34a:E2F1 positive feed-forward loop and the p53:miR-605:Mdm2 positive feedback loop.	nac	45-48	tumor protein p53	Homo sapiens	202-205	
24335178-14	2013	CONCLUSION: These findings not only indicate NAC as a rational approach for better treatment of cervical cancer with improved therapeutic outcomes, due partly to the ability of cisplatin to promote the p53:miR-34a:E2F1 positive feed-forward loop and the p53:miR-605:Mdm2 positive feedback loop.	nac	45-48	tumor protein p53	Homo sapiens	254-257	
22977494-9	2011	p53 overexpression may be a key predictor of a favorable response to NAC.	nac	69-72	tumor protein p53	Homo sapiens	0-3	
18510179-13	2008	The p53 Ab-negative patients may predict a high clinical OR rate in anthracycline-based NAC.	nac	88-91	tumor protein p53	Homo sapiens	4-7